Announcements Trials
Browse Landscape

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 23Observational 2Expanded_access 1

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Recurrence 2Urologic Neoplasms 1Urogenital Neoplasms 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Hepatocellular 1Carcinoma 1

Interventions

Blood Specimen Collection 31Sorafenib 29Nivolumab 29Bevacizumab 26Data Collection 24Observation 23palbociclib 22Sunitinib 22radium Ra 223 dichloride 20enzalutamide 18Rituximab 18Ipilimumab 16regorafenib 15Drug Therapy 15Trastuzumab 14Docetaxel 14ribociclib 12exemestane 12atezolizumab 12Standard of Care 12darolutamide 11apalutamide 11Leuprolide 11Capecitabine 11Afatinib 11Bortezomib 10Anastrozole 10trastuzumab deruxtecan 9pembrolizumab 9avelumab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Observational × Mitomycin × Clear all
NCT05874921 2025-02-28

uTRACT

UroGen Pharma Ltd.

Recruiting
400 enrolled
Genitourinary

Carcinoma, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Recurrence, Urogenital Neoplasms, Urologic Neoplasms

NCT00644020 2008-03-26

Phase â…¡Study of Tyroserleutide for Injection in Hepatocellular Carcinoma(HCC) Patients

Shenzhen Kangzhe Pharmaceutical Co., Ltd.

Unknown
100 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡